Overview

Efficacy and Safety of PRC-4016 in Subjects With Mixed Dyslipidemia

Status:
Terminated
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
The objective of this study is - To evaluate the efficacy of PRC-4016 by assessment of the percentage change in blood lipids and lipoprotein parameter from baseline after 12 weeks of treatment - To evaluate the safety of PRC-4016 as assessed by adverse events and other safety parameters
Phase:
Phase 2
Details
Lead Sponsor:
Pronova BioPharma
Treatments:
Hydroxymethylglutaryl-CoA Reductase Inhibitors